Session Details

F088 The Art of Healing- Scar Management Strategies Tailored to Ethnic Skin

Mon, Mar 10, 1:00 PM - 3:00 PM
W208A
2 CME Available Forum NEW
View Map

DESCRIPTION

Open admission to eligible categories, no tuition or ticket

In this session, you will encounter innovative approaches to scar treatment for different skin types. Experts will unveil scar treatment protocols that utilize a combination of lasers, cryotherapy, IPL, LLLT, injections, dressings, and garments, highlighting the differences in approaches while outlining treatment steps, parameters of the main devices, anti-fibrotic dosages, and combination treatments to achieve the best possible results for various skin tones. You will also learn how to address patients with severe cases of large burn scars and keloidal diathesis, particularly concerning their self-esteem. Additionally, techniques for scar refinement will be demonstrated, including repigmentation of achromic scars, treatment of hyperchromic scars, and management of atrophic scars.

LEARNING OBJECTIVES

1.

Use a step by step scar algorithm, that employs anti fibrotic drugs, dressings, pressure garments, lasers and other technologies, effective and safe in the treatment of keloids and scars in ethnic skin.

2.

Recognize patients prone to the development of different scar types- keloids, hypertrophic and atrophic scars. Identify risks when using technologies and treatments in ethnic skin and will also learn how to handle different technologies, as well as several types of scar treatments in various phototypes.

3.

Discuss scar treatment protocols with lasers, cryotherapy, IPL, LLLT, injections, dressings and garments- outline detailed scar treatment steps, parameters of the main devices, anti-fibrotic dosages and the combination treatments to achieve the best possible results.

SCHEDULE

5:00 PM

Step-by-step Scar and keloid treatment algorithm- how to start, when to use antifibrotic drugs and technologies, how to improve pigmentation and deliver natural outcomes

Gisele Viana Oliveira, MD, MSc, PhD, IFAAD

5:20 PM

Antifibrotic drugs, antineoplastic, steroids, verapamil, botulinum toxin- when and how? Tips and tricks to avoid side-effects in higher phototypes

Leandra d'Orsi Metsavaht, MD, IFAAD

5:35 PM

Ethnic skin considerations before choosing the scars treatment. When to consider surgical approach?

Daniela Araucaria Guzman Sanchez, MD, IFAAD

5:50 PM

Combination of Lasers and technologies to treat scars and keloids in higher phototypes.

Michael H. Gold, MD, FAAD

6:05 PM

Final improvement of scars using Fillers, botulinum toxin and biostimulators - tricks and challenges in ethnic skin

Doris M Hexsel, MD, IFAAD

6:20 PM

Comprehensive management of acne scarring.

Alexandra Y. Zhang, MD, FAAD

6:35 PM

How to prevent Scar Formation

Alvaro Andres Luque Acevedo, MD, IFAAD

6:50 PM

Questions/bring your case to discuss with experts

SPEAKERS

Michael H. Gold, MD, FAAD

Michael H. Gold, MD, FAAD

Daniela Araucaria Guzman Sanchez, MD, IFAAD

Daniela Araucaria Guzman Sanchez, MD, IFAAD

Doris M Hexsel, MD, IFAAD

Doris M Hexsel, MD, IFAAD

Alvaro Andres Luque Acevedo, MD, IFAAD

Alvaro Andres Luque Acevedo, MD, IFAAD

Leandra d'Orsi Metsavaht, MD, IFAAD

Leandra d'Orsi Metsavaht, MD, IFAAD

Gisele Viana Oliveira, MD, MSc, PhD, IFAAD

Gisele Viana Oliveira, MD, MSc, PhD, IFAAD

Alexandra Y. Zhang, MD, FAAD

Alexandra Y. Zhang, MD, FAAD

HANDOUTS

Login to view handouts

SPEAKER DISCLOSURES

Michael H. Gold, MD, FAAD

Acclaro Medical – Consultant (1099 relationship)(Honoraria); Aerolase – Stockholder(Honoraria); Aesthetic Management Partners – Consultant (1099 relationship)(Honoraria); Aesthetics Biomedical – Consultant (1099 relationship)(Honoraria); Alastin Skincare, Inc – Consultant (1099 relationship)(Honoraria); Allergan, Inc – Consultant(Honoraria); Alma Lasers – Speaker(Honoraria); Bausch Health – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Benev – Consultant (1099 relationship)(Honoraria); Cutera, Inc. – Speaker(Honoraria); EndyMed Medical Inc. USA – Speaker(Honoraria); Galderma – Consultant (1099 relationship)(Honoraria); Hugel – Consultant (1099 relationship)(Honoraria); InMode – Consultant (1099 relationship)(Honoraria); La Mer – Consultant (1099 relationship)(Honoraria); Leo Pharma Inc – Investigator(Grants/Research Funding); Lumenis – Speaker(Honoraria); Merz Pharmaceuticals, LLC – Speaker(Honoraria); Mindera – Consultant (1099 relationship)(Honoraria); MTF Biologics – Consultant (1099 relationship)(Honoraria); Nutrafol – Consultant (1099 relationship)(Honoraria); Pierre Fabre – Consultant (1099 relationship)(Honoraria); Prescriber's Choice – Consultant (1099 relationship)(Honoraria); Revance Therapeutics, Inc. – Investigator(Grants/Research Funding); Revision Skincare – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Rohrer Aesthetics – Consultant (1099 relationship)(Honoraria); Sciton Inc. – Consultant (1099 relationship)(Honoraria); Sensus Healthcare – Consultant (1099 relationship)(Honoraria); Sente Labs – Consultant (1099 relationship)(Honoraria); SkinBetter Science – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); SkinCeuticals LLC – Consultant (1099 relationship)(Honoraria); SkinMedica, Inc. – Consultant (1099 relationship)(Honoraria); Sofwave – Consultant (1099 relationship)(Honoraria); Stratapharma – Consultant (1099 relationship)(Honoraria); Venus Concept – Consultant(Stock Options), Speaker(Honoraria); VIOL – Consultant (1099 relationship)(Honoraria);

Daniela Araucaria Guzman Sanchez, MD, IFAAD

No financial relationships exist with ineligible companies.

Doris M Hexsel, MD, IFAAD

No financial relationships exist with ineligible companies.

Alvaro Andres Luque Acevedo, MD, IFAAD

No financial relationships exist with ineligible companies.

Leandra d'Orsi Metsavaht, MD, IFAAD

No financial relationships exist with ineligible companies.

Gisele Viana Oliveira, MD, MSc, PhD, IFAAD

No financial relationships exist with ineligible companies.

Alexandra Y. Zhang, MD, FAAD

No financial relationships exist with ineligible companies.